Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AC Immune (ACIU : NSDQ)
 
 • Company Description   
AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.

Number of Employees: 172

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.11 Daily Weekly Monthly
20 Day Moving Average: 117,140 shares
Shares Outstanding: 100.41 (millions)
Market Capitalization: $211.87 (millions)
Beta: 1.62
52 Week High: $4.26
52 Week Low: $1.43
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.93% -1.88%
12 Week 42.57% 19.92%
Year To Date -21.85% -26.82%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
EPFL INNOVATION PARK BUILDING B
-
LAUSANNE,V8 1015
CHE
ph: 41-21-345-9121
fax: 41-21-345-9120
ir@acimmune.com http://www.acimmune.com
 
 • General Corporate Information   
Officers
Andrea Pfeifer - Chief Executive Officer
Douglas Williams - Chair and Director
Monika Butler - Vice Chair and Director
Piergiorgio Donati - Chief Operations Officer
Christopher Roberts - Chief Financial Officer

Peer Information
AC Immune (CORR.)
AC Immune (RSPI)
AC Immune (CGXP)
AC Immune (BGEN)
AC Immune (GTBP)
AC Immune (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: H00263105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 100.41
Most Recent Split Date: (:1)
Beta: 1.62
Market Capitalization: $211.87 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.82 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.01
Price/Cash Flow: -
Price / Sales: 6.50
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -16.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -15.05%
ROE
06/30/25 - -
03/31/25 - -44.60
12/31/24 - -39.49
ROA
06/30/25 - -
03/31/25 - -22.25
12/31/24 - -22.93
Current Ratio
06/30/25 - -
03/31/25 - 1.53
12/31/24 - 1.71
Quick Ratio
06/30/25 - -
03/31/25 - 1.53
12/31/24 - 1.71
Operating Margin
06/30/25 - -
03/31/25 - -177.79
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -177.79
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -179.67
12/31/24 - -186.43
Book Value
06/30/25 - -
03/31/25 - 1.05
12/31/24 - 1.29
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©